11 – 20 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival.
(
- Contribution to journal › Letter
-
Mark
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
(
- Contribution to journal › Article
-
Mark
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
(
- Contribution to journal › Article
- 2014
-
Mark
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F
(
- Contribution to journal › Article
-
Mark
Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.
(
- Contribution to journal › Article
- 2013
-
Mark
Patterns of survival in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: A population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005
(
- Contribution to journal › Article
-
Mark
Medicinska framsteg i behandling av kronisk myeloisk leukemi
2013)(
- Other contribution › Miscellaneous
-
Mark
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
(
- Contribution to journal › Article